Key result
ACEI use linked to ~16% lower 3-year major cardiovascular events risk vs. ARB in normotensive AMI patients.
Why the study?
Does ACEI reduce MACE in acute myocardial infarction patients without a history of hypertension undergoing successful PCI compared to ARB?
Observational (n=3,993)
Yes
Does ACEI reduce MACE in acute myocardial infarction patients without a history of hypertension undergoing successful PCI compared to ARB?
In AMI patients without hypertension undergoing PCI, the use of ACEI significantly reduced long-term MACE, stroke, and heart failure rehospitalization compared to ARB.
Answers are grounded in this paper and cite their sources.
ACEI may be preferable to ARB in normotensive AMI post-PCI; leaves open confirmation in randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yusuf et al. (2005) conducted an observational in Acute Myocardial Infarction without Hypertension (n=3,993). Angiotensin-converting-enzyme inhibitors (ACEI) vs. Angiotensin II type 1 receptor blockers (ARB) was evaluated on Major adverse cardiac events (MACE) defined as a composite of all-cause death, recurrent myocardial infarction, and any repeat revascularization (HR 0.843, 95% CI 0.740-0.960, p=0.010). Exposure to ACEI reduced the 3-year risk of major adverse cardiac events by 15.7% compared to ARB in acute myocardial infarction patients without a history of hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: